ATE338761T1 - Pharmazeutisch unbedenkliche alendronatsalze in amorpher form - Google Patents

Pharmazeutisch unbedenkliche alendronatsalze in amorpher form

Info

Publication number
ATE338761T1
ATE338761T1 AT02801429T AT02801429T ATE338761T1 AT E338761 T1 ATE338761 T1 AT E338761T1 AT 02801429 T AT02801429 T AT 02801429T AT 02801429 T AT02801429 T AT 02801429T AT E338761 T1 ATE338761 T1 AT E338761T1
Authority
AT
Austria
Prior art keywords
amorphous form
pharmaceutically safe
alendronate
salts
alendronate salts
Prior art date
Application number
AT02801429T
Other languages
English (en)
Inventor
Yusuf Khwaja Hamied
Dhanmaraj Ramachandra Shri Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE338761(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of ATE338761T1 publication Critical patent/ATE338761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02801429T 2001-10-18 2002-10-18 Pharmazeutisch unbedenkliche alendronatsalze in amorpher form ATE338761T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0125081A GB2383042A (en) 2001-10-18 2001-10-18 Amorphous alendronate sodium

Publications (1)

Publication Number Publication Date
ATE338761T1 true ATE338761T1 (de) 2006-09-15

Family

ID=9924125

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801429T ATE338761T1 (de) 2001-10-18 2002-10-18 Pharmazeutisch unbedenkliche alendronatsalze in amorpher form

Country Status (21)

Country Link
US (1) US7112577B2 (de)
EP (1) EP1436303B1 (de)
JP (1) JP4490100B2 (de)
KR (1) KR20040053186A (de)
AT (1) ATE338761T1 (de)
AU (1) AU2002334200B2 (de)
BR (1) BR0213398A (de)
CA (1) CA2463815C (de)
CL (1) CL2004001372A1 (de)
DE (1) DE60214576T2 (de)
EC (1) ECSP045067A (de)
ES (1) ES2271375T3 (de)
GB (1) GB2383042A (de)
IL (1) IL161360A0 (de)
MX (1) MXPA04003549A (de)
NZ (1) NZ532292A (de)
PT (1) PT1436303E (de)
RU (1) RU2334751C2 (de)
TN (1) TNSN04067A1 (de)
WO (1) WO2003033508A1 (de)
ZA (1) ZA200403024B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100897837B1 (ko) * 2001-12-24 2009-05-15 테바 파마슈티컬 인더스트리즈 리미티드 분말 또는 과립 물질의 압착된 환상체 내에 싸인 활성성분의 코어 정제를 갖는 제형과, 이의 제조 방법 및 툴링
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
SK50782006A3 (sk) † 2004-02-26 2007-03-01 Zentiva, A. S. Amorfné formy risedronátu monosodného
EP1571152B1 (de) * 2004-03-03 2007-08-08 CHEMI S.p.A. Amorphe 3-Pyridyl-1-Hydroxyethyliden-1,1-Bisphosphonsäure Mononatriumsalz und Verfahren zu deren Herstellung
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
KR20150053963A (ko) * 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2017193914A1 (zh) * 2016-05-09 2017-11-16 苏州科睿思制药有限公司 克立硼罗游离形式的晶型及其制备方法和用途
JP2019518058A (ja) * 2016-06-16 2019-06-27 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物の固体状態形
EP3510021A1 (de) * 2016-09-06 2019-07-17 Indena S.p.A. Feste formen von ingenol-3-(3,5-diethylisoxazol-4-carboxylat) und verfahren zur herstellung davon
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
IL288737B (en) * 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
KR102777452B1 (ko) * 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
EP3773753A4 (de) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Behandlung von hcv-infizierten patienten mit zirrhose
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
WO2000012517A1 (en) 1998-08-27 2000-03-09 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1135397B1 (de) * 1998-12-10 2003-04-23 Aesgen, Inc. Verfahren zur herstellung von dinatriumpamidronat
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
WO2001030788A1 (en) 1999-10-26 2001-05-03 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use

Also Published As

Publication number Publication date
DE60214576T2 (de) 2007-08-30
EP1436303A1 (de) 2004-07-14
DE60214576D1 (de) 2006-10-19
ZA200403024B (en) 2005-03-30
JP4490100B2 (ja) 2010-06-23
JP2005521636A (ja) 2005-07-21
KR20040053186A (ko) 2004-06-23
NZ532292A (en) 2005-07-29
BR0213398A (pt) 2005-01-11
TNSN04067A1 (en) 2006-06-01
CA2463815A1 (en) 2003-04-24
CA2463815C (en) 2009-04-07
RU2004113306A (ru) 2005-10-10
RU2334751C2 (ru) 2008-09-27
HK1066011A1 (en) 2005-03-11
CL2004001372A1 (es) 2005-05-06
US7112577B2 (en) 2006-09-26
IL161360A0 (en) 2004-09-27
WO2003033508A1 (en) 2003-04-24
ES2271375T3 (es) 2007-04-16
GB2383042A (en) 2003-06-18
ECSP045067A (es) 2004-07-23
PT1436303E (pt) 2006-12-29
GB0125081D0 (en) 2001-12-12
US20040259846A1 (en) 2004-12-23
MXPA04003549A (es) 2004-07-22
AU2002334200B2 (en) 2008-04-03
EP1436303B1 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
ATE338761T1 (de) Pharmazeutisch unbedenkliche alendronatsalze in amorpher form
NO2022032I1 (no) Elvitegravir or a pharmaceutically acceptable salt thereof - Forlenget SPC
NO2022028I1 (no) Afatinib - tautomers, stereoisomers og salts thereof - forlengelse SPC
NO2023006I1 (no) Tenofovir alafenamide or a salt or solvate thereof, especially tenofovir alafenamide fumarate - forlengelse
DK1313714T3 (da) Valsartansalte
NO20033815L (no) Farmasöytiske salter
NO20022822D0 (no) Kraftforsyningssystem for en brönn
EP1469812A4 (de) Orale insulintherapie
ATE413612T1 (de) Dreidimensionaler bildprojektor
DE60121540D1 (de) Drehwinkelverstellungseinrichtung
EP1648421A4 (de) Oral lösliche filme
DE60213696D1 (de) Sekundär-Energiequelle
DK1414824T3 (da) Nye antikonvulsive derivatsalte
DE60137795D1 (de) Negativionenerzeuger
DE60207081D1 (de) Hybridaufblasvorrichtung
PL361803A1 (pl) Sposób zobojętniania popiołu, sztuczna pucolana otrzymana przy użyciu wymienionego sposobu
FI20011147L (fi) Menetelmä kolmiuloitteisten pintojen kuviointiin
PL373794A1 (en) New salts
FR2818814B1 (fr) Source laser
NO20006447L (no) Bölgeleder-laserkilde
FI20021053A0 (fi) Menetelmä kolmiulotteisten pintojen kuviointiin
IS6007A (is) Ný morfólínóbensamíðsölt
GB0206708D0 (en) Pharmaceutical salts
FI20010104A0 (fi) Laite energian tuottamiseen
SE0001942D0 (sv) A device for generating energy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties